‘Acute renal impairment’ warning added on Forxiga & Invokana
The Ministry of Food and Drug Safety(MFDS) gave an advance notice in regards to changes in the approval details of antidiabetic SGLT-2 inhibitors, ‘Forxiga(dapagliflozin)’ and ‘Invokana(canagliflozin)’ with the process of collecting opinions. The part to warn acute renal impairment was added.
...Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
